A top five CRO has signed a Master Services Agreement (MSA) with  

, reports the Santa Clara, CA-based cardiac diagnostic and services company. The agreement gives the unspecified CRO a license to use NewCardio's QTinno software, which, according to the company's 

, "provides fully automated and comprehensive analysis of QT intervals and other ECG markers for cardiac safety assessment in drug development."

"The adoption of QTinno by the clinical pharmacology units at this top five CRO will enable them to deliver quality TQT/QT studies with higher accuracy and lower intrinsic variability in a timely and cost-effective manner," says Vincent Renz, NewCardio's President and Chief Operating Officer, in a company press release.

By adding this software to  its existing offerings, the CRO will also be able to "capture additional" revenue because it will be able to provide customers with more services, the press release reports.